1. Home
  2. NMRA vs RCS Comparison

NMRA vs RCS Comparison

Compare NMRA & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • RCS
  • Stock Information
  • Founded
  • NMRA 2019
  • RCS 1994
  • Country
  • NMRA United States
  • RCS United States
  • Employees
  • NMRA N/A
  • RCS N/A
  • Industry
  • NMRA
  • RCS Investment Managers
  • Sector
  • NMRA
  • RCS Finance
  • Exchange
  • NMRA Nasdaq
  • RCS Nasdaq
  • Market Cap
  • NMRA 287.6M
  • RCS 292.8M
  • IPO Year
  • NMRA 2023
  • RCS N/A
  • Fundamental
  • Price
  • NMRA $0.91
  • RCS $6.25
  • Analyst Decision
  • NMRA Buy
  • RCS
  • Analyst Count
  • NMRA 8
  • RCS 0
  • Target Price
  • NMRA $10.14
  • RCS N/A
  • AVG Volume (30 Days)
  • NMRA 1.2M
  • RCS 141.1K
  • Earning Date
  • NMRA 03-03-2025
  • RCS 01-01-0001
  • Dividend Yield
  • NMRA N/A
  • RCS 10.12%
  • EPS Growth
  • NMRA N/A
  • RCS N/A
  • EPS
  • NMRA N/A
  • RCS N/A
  • Revenue
  • NMRA N/A
  • RCS N/A
  • Revenue This Year
  • NMRA N/A
  • RCS N/A
  • Revenue Next Year
  • NMRA N/A
  • RCS N/A
  • P/E Ratio
  • NMRA N/A
  • RCS N/A
  • Revenue Growth
  • NMRA N/A
  • RCS N/A
  • 52 Week Low
  • NMRA $0.90
  • RCS $4.51
  • 52 Week High
  • NMRA $17.19
  • RCS $6.31
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 23.28
  • RCS 46.51
  • Support Level
  • NMRA $1.12
  • RCS $6.16
  • Resistance Level
  • NMRA $1.13
  • RCS $6.34
  • Average True Range (ATR)
  • NMRA 0.09
  • RCS 0.08
  • MACD
  • NMRA 0.03
  • RCS 0.00
  • Stochastic Oscillator
  • NMRA 2.47
  • RCS 40.91

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

About RCS PIMCO Strategic Income Fund Inc.

PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.

Share on Social Networks: